课题基金 / 基金详情

University of Hawaii Cancer Center CCSG

University of Hawaii Cancer Center CCSG
夏威夷大学癌症中心 CCSG
批准号:
9526161
负责人:
RANDALL F HOLCOMBE
金额:
$215.6万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-07-01 至 2018-06-30

项目摘要

项目成果

RANDALL F HOLCOMBE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请寻求为夏威夷大学癌症中心(UHCC)提供新的CCSG资金,UHCC是夏威夷州和太平洋地区唯一进行癌症研究的机构。作为世界上一个健康差异显著的地区的前哨站,UHCC在将关于如何预防和治疗癌症的尖端基础,转化和临床研究带到独特的区域人口范围内方面发挥着关键作用。UHCC是新的夏威夷癌症联盟(HCC)的一部分,沿着夏威夷的三大医院系统。该联盟使UHCC能够开发新的临床项目,并扩大其临床和转化研究,以开发新的诊断和治疗方法。到2017年,HCC机构每年向UHCC承诺220万美元,UHCC从NCI获得2320万美元,从其他同行评审来源获得1800万美元,总共获得4120万美元的同行评审赠款资金。UHCC/HCC最近招募了一名新主任,沿着还有30名教师,他们带来了广泛的科学和临床技能。这些新成员帮助UHCC/HCC继续建立和加强其基础科学基础,并大大提高其加速临床和转化癌症研究的能力。为了加强跨学科和转化研究,三个研究计划(癌症生物学,癌症流行病学和癌症预防和控制)已经重组,以提供更好的重点在其研究领域。UHCC的所有项目都由新董事领导,每个董事都致力于增加其项目的活力和互动。此外,规划和评价 对调查员进行了改组,以便为调查员创造更多的互动机会,并随时了解合作机会。该应用程序请求支持7个共享资源(分析生物化学,生物统计学和信息学,基因组学,显微镜和成像,营养支持,病理学,临床和转化研究服务)和一个开发共享资源(动物致癌)。在研究设施的主要增加包括一个新的150,000平方英尺的UHCC研究大楼在2012年开放,将共同容纳我们不断增长的教师,夏威夷大学已经批准了18个新的终身职位为UHCC的跟踪位置。该申请描述了基础和转化癌症研究的持续卓越,并大大加强了临床研究领导和基础设施。
英文摘要
DESCRIPTION (provided by applicant): This application seeks renewed CCSG funding for the University of Hawai'i Cancer Center (UHCC), the state of Hawai'i and the Pacific Region's only institution where cancer research is performed. As an outpost in an area of the world with significant health disparities, UHCC serves a critical function in bringing cutting edge basic, translational, and clinical research on how to prevent and treat cancer within reach of the unique regional population. UHCC is part of the new Hawai'i Cancer Consortium (HCC) along with the 3 major hospital systems of Hawai'i. This consortium enables UHCC to develop a new clinical program and expand its clinical and translational research towards the development of new diagnostics and therapies. HCC institutions have committed $2.2 million annually towards UHCC through 2017, and UHCC receives $23.2M from the NCI and $18M from other peer-reviewed sources for a total of $41.2M in overall peer-reviewed grant funding. UHCC/HCC has recently recruited a new Director, along with 30 additional faculty members, who bring with them a broad-spectrum of scientific and clinical skills. These new recruits have helped UHCC/HCC continue to build and strengthen its basic-science foundations and to greatly enhance its ability to accelerate clinical and translational cancer research. To enhance their transdisciplinary and translational research, the three Research Programs (Cancer Biology, Cancer Epidemiology, and Cancer Prevention and Control) have been reorganized to provide a better focus in their areas of research. All Programs at UHCC are led by new Directors, each dedicated to increasing the vitality and interaction of their Programs. In addition, Planning and Evaluation has been restructured to create more opportunities for investigators to interact and stay abreast of opportunities for collaboration. This application requests support for 7 Shared Resources (Analytical Biochemistry, Biostatistics and Informatics, Genomics, Microscopy and Imaging, Nutrition Support, Pathology, and Clinical and Translational Research Services), and one developing Shared Resource (Animal Carcinogenesis). Major additions in research facilities include a new 150,000-sq ft UHCC research building opening in 2012 that will collectively house our growing faculty, as the University of Hawai'i has approved a total of 18 new tenure track positions for UHCC. This application describes continued excellence in basic and translational cancer research, and greatly strengthened clinical research leadership and infrastructure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neoadjuvant photodynamic immunomodulation for colon cancer
  • 批准号:
    8005456
  • 项目类别:
  • 资助金额:
    $29.82万
  • 财政年份:
    2010
  • 负责人:
    RANDALL F HOLCOMBE
  • 依托单位:
Neoadjuvant photodynamic immunomodulation for colon cancer
  • 批准号:
    8119595
  • 项目类别:
  • 资助金额:
    $30.21万
  • 财政年份:
    2010
  • 负责人:
    RANDALL F HOLCOMBE
  • 依托单位:
PHASE I BIOMARKER STUDY OF DIETARY GRAPE-DERIVED LOW DOSE RESVERATROL FOR COLON
PHASE I BIOMARKER STUDY OF DIETARY GRAPE-DERIVED LOW DOSE RESVERATROL FOR COLON
海外基金